Respiratory Viral Infection
G.ST Antivirals GmbH is focused on rhinovirus-associated illness, with research centered on preventing symptomatic infection in healthy adults exposed to human rhinovirus.
- Rhinovirus-associated illness
- Human rhinovirus
- Respiratory infection prevention
The sponsor’s current clinical research activity is directed toward antiviral intervention in a controlled infectious disease setting.
Antiviral Therapeutics
The company’s therapeutic interest includes antiviral treatment strategies aimed at limiting the development of illness after viral exposure, with attention to small-molecule approaches.
- Antiviral treatment
- Small-molecule therapy
- Illness prevention
Its research profile reflects a narrow focus on therapies intended to interfere with viral disease onset.
Experimental Human Infection Research
G.ST Antivirals GmbH is involved in controlled human infection research, supporting evaluation of antiviral candidates under direct viral challenge conditions.
- Controlled human infection
- Viral challenge models
- Healthy volunteer studies
This area of interest is closely tied to understanding how candidate therapies perform against acute respiratory viral exposure.
Metabolic Antiviral Targeting
The sponsor also shows interest in 2-Deoxy-D-Glucose as a therapeutic candidate, indicating attention to metabolic interference as a possible antiviral strategy.
- 2-Deoxy-D-Glucose
- Metabolic interference
- Host-targeted antiviral strategy
Its research activity suggests a focus on host-pathway modulation in the context of respiratory viral illness.
